ARWR ARROWHEAD PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 879407 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $38.04M 20 sales by 10 insiders
- Filings on record
- 139 since 2021-09-10, latest 2026-08-20 17:25
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Anzalone Christopher Richard | CEO, Dir | — | $24.01M |
| Hamilton James C | Chief Medical Off | — | $4.63M |
| O'Brien Patrick | COO | — | $3.12M |
| PERRY MICHAEL S | Dir | — | $2.00M |
| Ferrari Mauro | Dir | — | $1.02M |
| Apel Daniel Joseph | CFO | — | $934.3K |
| OLUKOTUN ADEOYE Y | Dir | — | $850.5K |
| Vakiener Victoria | Dir | — | $679.5K |
| Waddill William D. | Dir | — | $566.0K |
| Lu Hongbo | Dir | — | $228.3K |
Transactions 165
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-20 | 2023-09-18 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $4.75 | +57.8K | 3.82M | +2% | +$274.3K |
| 2023-07-06 | 2023-07-03 | ARWR | Oliver Tracie | Chief Commercial Off | S - Sale | $35.31 | -8,925 | 61.6K | -13% | -$315.1K | |
| 2023-07-05 | 2023-06-30 | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | S - Sale | $35.53 | -3,000 | 188.5K | -2% | -$106.6K | |
| 2023-06-29 | 2023-06-27 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $36.20 | -15.0K | 381.7K | -4% | -$543.0K | |
| 2023-05-08 | 2023-05-05 | ARWR | GIVEN DOUGLAS B | Dir | S - Sale | $40.90 | -6,500 | 117.6K | -5% | -$265.9K | |
| DM | 2023-05-05 | 2023-05-03+ | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale+OE | $39.32 | -104.9K | 3.76M | -3% | -$4.13M |
| DM | 2023-05-05 | 2023-05-03+ | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $2.01 | +104.9K | 3.81M | +3% | +$210.9K |
| 2023-03-06 | 2023-03-03 | ARWR | OLUKOTUN ADEOYE Y | Dir | S - Sale | $32.65 | -11.3K | 7,867 | -59% | -$370.6K | |
| I | 2023-03-01 | 2023-02-27 | ARWR | GIVEN DOUGLAS B | Dir | S - Sale | $32.62 | -875 | 13.0K | -6% | -$28.5K |
| D | 2023-01-12 | 2023-01-10 | ARWR | Ferrari Mauro | Dir | A - Grant | $0.00 | +7,867 | 50.8K | +18% | $0 |
| D | 2023-01-11 | 2023-01-10 | ARWR | GIVEN DOUGLAS B | Dir | A - Grant | $0.00 | +7,867 | 124.1K | +7% | $0 |
| D | 2023-01-11 | 2023-01-10 | ARWR | Vakiener Victoria | Dir | A - Grant | $0.00 | +7,867 | 23.3K | +51% | $0 |
| D | 2023-01-11 | 2023-01-10 | ARWR | Vakiener Victoria | Dir | D - Sale to Iss | $0.00 | -1,764 | 15.4K | -10% | $0 |
| D | 2023-01-11 | 2023-01-09 | ARWR | Waddill William D. | Dir | S - Sale | $30.00 | -3,200 | 28.9K | -10% | -$96.0K |
| D | 2023-01-11 | 2023-01-10 | ARWR | Waddill William D. | Dir | A - Grant | $0.00 | +7,867 | 36.8K | +27% | $0 |
| D | 2023-01-11 | 2023-01-10 | ARWR | OLUKOTUN ADEOYE Y | Dir | A - Grant | $0.00 | +7,867 | 19.2K | +69% | $0 |
| D | 2023-01-11 | 2023-01-10 | ARWR | De Backer Marianne | Dir | A - Grant | $0.00 | +7,867 | 31.3K | +34% | $0 |
| D | 2023-01-11 | 2023-01-10 | ARWR | PERRY MICHAEL S | Dir | A - Grant | $0.00 | +7,867 | 99.8K | +9% | $0 |
| M | 2023-01-06 | 2023-01-05 | ARWR | O'Brien Patrick | COO, GC | S - Sale | $37.39 | -15.0K | 420.9K | -3% | -$560.9K |
| M | 2023-01-06 | 2023-01-05 | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | S - Sale | $37.40 | -13.8K | 191.5K | -7% | -$516.2K |
| 2023-01-05 | 2023-01-04 | ARWR | Oliver Tracie | Chief Commercial Off | A - Grant | $0.00 | +500 | 70.5K | +0.7% | $0 | |
| 2023-01-05 | 2023-01-04 | ARWR | Myszkowski Kenneth Allen | CFO | A - Grant | $0.00 | +60.0K | 396.7K | +18% | $0 | |
| M | 2023-01-05 | 2023-01-03 | ARWR | O'Brien Patrick | COO, GC | S - Sale | $38.33 | -17.5K | 372.1K | -4% | -$670.8K |
| 2023-01-05 | 2023-01-04 | ARWR | O'Brien Patrick | COO, GC | A - Grant | $0.00 | +65.0K | 428.4K | +18% | $0 | |
| M | 2023-01-05 | 2023-01-03 | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | S - Sale | $38.38 | -10.3K | 151.3K | -6% | -$396.7K |
| 2023-01-05 | 2023-01-04 | ARWR | Hamilton James C | Chief Discovery, Trans Medicine | A - Grant | $0.00 | +60.0K | 205.3K | +41% | $0 | |
| 2023-01-05 | 2023-01-04 | ARWR | San Martin Javier | Chief Medical Off | A - Grant | $0.00 | +60.0K | 151.5K | +66% | $0 | |
| 2022-12-30 | 2022-12-29 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $40.00 | -30.6K | 336.7K | -8% | -$1.23M | |
| D | 2022-12-22 | 2022-12-21 | ARWR | O'Brien Patrick | GC | M - OptEx | $6.15 | +32.0K | 380.9K | +9% | +$196.8K |
| M | 2022-12-20 | 2022-12-16+ | ARWR | Anzalone Christopher Richard | CEO, Dir | A - Grant | $0.00 | +252.4K | 3.72M | +7% | $0 |
| M | 2022-11-22 | 2022-11-21 | ARWR | San Martin Javier | Chief Medical Off | S - Sale | $29.99 | -19.5K | 91.7K | -18% | -$584.7K |
| M | 2022-09-29 | 2022-09-27 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $30.79 | -40.6K | 3.47M | -1% | -$1.25M |
| 2022-07-12 | 2022-07-08 | ARWR | Anzalone Christopher Richard | CEO, Dir | D - Sale to Iss | $0.00 | -551.2K | 3.51M | -14% | $0 | |
| D | 2022-07-11 | 2022-07-07 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $14.54 | +2,501 | 4.06M | +0.1% | +$36.4K |
| DM | 2022-02-14 | 2022-02-11 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale+OE | $51.91 | -146.4K | 4.16M | -3% | -$7.60M |
| D | 2022-02-14 | 2022-02-11 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $5.19 | +146.4K | 4.20M | +4% | +$759.8K |
| 2022-01-07 | 2022-01-07 | ARWR | OLUKOTUN ADEOYE Y | Dir | A - Grant | $0.00 | +6,400 | 11.3K | +129% | $0 | |
| 2022-01-07 | 2022-01-07 | ARWR | De Backer Marianne | Dir | A - Grant | $0.00 | +6,400 | 23.4K | +38% | $0 | |
| 2022-01-07 | 2022-01-07 | ARWR | GIVEN DOUGLAS B | Dir | A - Grant | $0.00 | +6,400 | 116.3K | +6% | $0 | |
| 2022-01-07 | 2022-01-07 | ARWR | Waddill William D. | Dir | A - Grant | $0.00 | +6,400 | 32.1K | +25% | $0 | |
| 2022-01-07 | 2022-01-07 | ARWR | PERRY MICHAEL S | Dir | A - Grant | $0.00 | +6,400 | 91.9K | +7% | $0 | |
| M | 2022-01-07 | 2022-01-05 | ARWR | O'Brien Patrick | GC | S - Sale | $61.72 | -32.5K | 348.9K | -9% | -$2.01M |
| 2022-01-07 | 2020-12-04 | ARWR | O'Brien Patrick | GC | G - Gift | $0.00 | -800 | 348.1K | -0.2% | $0 | |
| 2022-01-07 | 2022-01-07 | ARWR | Ferrari Mauro | Dir | A - Grant | $0.00 | +6,400 | 43.0K | +18% | $0 | |
| D | 2022-01-07 | 2022-01-07 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $5.19 | +11.8K | 4.06M | +0.3% | +$61.3K |
| M | 2022-01-06 | 2022-01-05 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $61.70 | -40.0K | 471.6K | -8% | -$2.47M |
| M | 2022-01-06 | 2022-01-04+ | ARWR | Hamilton James C | SVP | S - Sale | $64.57 | -25.6K | 162.4K | -14% | -$1.65M |
| M | 2022-01-04 | 2022-01-03 | ARWR | OLUKOTUN ADEOYE Y | Dir | S - Sale | $64.75 | -4,050 | 7,110 | -36% | -$262.2K |
| M | 2022-01-04 | 2022-01-03 | ARWR | PERRY MICHAEL S | Dir | S - Sale | $64.71 | -4,500 | 87.4K | -5% | -$291.2K |
| 2022-01-04 | 2022-01-01 | ARWR | Hamilton James C | SVP | A - Grant | $0.00 | +55.0K | 181.2K | +44% | $0 | |
| M | 2022-01-04 | 2022-01-03 | ARWR | De Backer Marianne | Dir | S - Sale | $64.71 | -4,500 | 17.0K | -21% | -$291.2K |
| D | 2022-01-04 | 2022-01-01 | ARWR | O'Brien Patrick | GC | A - Grant | $0.00 | +60.0K | 381.4K | +19% | $0 |
| D | 2022-01-04 | 2021-12-31 | ARWR | O'Brien Patrick | GC | M - OptEx | $6.15 | +28.0K | 321.4K | +10% | +$172.2K |
| 2022-01-04 | 2022-01-01 | ARWR | Anzalone Christopher Richard | CEO, Dir | A - Grant | $0.00 | +800.0K | 4.05M | +25% | $0 | |
| 2022-01-04 | 2022-01-01 | ARWR | Myszkowski Kenneth Allen | CFO | A - Grant | $0.00 | +60.0K | 504.0K | +14% | $0 | |
| M | 2022-01-04 | 2022-01-03 | ARWR | Waddill William D. | Dir | S - Sale | $64.72 | -4,500 | 26.0K | -15% | -$291.2K |
| 2021-12-29 | 2021-12-28 | ARWR | Ferrari Mauro | Dir | S - Sale | $66.82 | -3,400 | 36.6K | -9% | -$227.2K | |
| 2021-12-29 | 2021-12-28 | ARWR | GIVEN DOUGLAS B | Dir | G - Gift | $0.00 | -655 | 109.2K | -0.6% | $0 | |
| 2021-12-29 | 2021-12-28 | ARWR | GIVEN DOUGLAS B | Dir | P - Purchase | $66.37 | +655 | 109.9K | +0.6% | +$43.5K | |
| D | 2021-12-23 | 2021-12-23 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $5.19 | +11.8K | 3.25M | +0.4% | +$61.3K |
| M | 2021-12-17 | 2021-12-15 | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $67.56 | -60.0K | 3.25M | -2% | -$4.05M |
| M | 2021-11-22 | 2021-11-19 | ARWR | San Martin Javier | Chief Medical Off | S - Sale | $69.31 | -19.5K | 111.0K | -15% | -$1.35M |
| M | 2021-10-22 | 2021-10-20+ | ARWR | Anzalone Christopher Richard | CEO, Dir | S - Sale | $65.77 | -65.0K | 3.28M | -2% | -$4.27M |
| M | 2021-09-14 | 2021-09-13 | ARWR | OLUKOTUN ADEOYE Y | Dir | S - Sale | $63.76 | -5,000 | 9,000 | -36% | -$318.8K |
| 2021-09-10 | 2021-09-09 | ARWR | GIVEN DOUGLAS B | Dir | S - Sale | $65.24 | -5,000 | 109.9K | -4% | -$326.2K |
Purchase Sale Sale after option exercise All abbreviations